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Background: Environment inside even a small tumor is characterized by total (anoxia) or partial oxygen
deprivation, (hypoxia). It has been shown that radiotherapy and some conventional chemotherapies may be less
effective in hypoxia, and therefore it is important to investigate how different drugs act in different
microenvironments. In this study we perform a large screening of the effects of 19 clinically used or experimental
chemotherapeutic drugs on five different cell lines in conditions of normoxia, hypoxia and anoxia.
Methods: A panel of 19 commercially available drugs: 5-fluorouracil, acriflavine, bortezomib, cisplatin, digitoxin,
digoxin, docetaxel, doxorubicin, etoposide, gemcitabine, irinotecan, melphalan, mitomycin c, rapamycin, sorafenib,
thalidomide, tirapazamine, topotecan and vincristine were tested for cytotoxic activity on the cancer cell lines
A2780 (ovarian), ACHN (renal), MCF-7 (breast), H69 (SCLC) and U-937 (lymphoma). Parallel aliquots of the cells were
grown at different oxygen pressures and after 72 hours of drug exposure viability was measured with the
fluorometric microculture cytotoxicity assay (FMCA).
Results: Sorafenib, irinotecan and docetaxel were in general more effective in an oxygenated environment, while
cisplatin, mitomycin c and tirapazamine were more effective in a low oxygen environment. Surprisingly, hypoxia in
H69 and MCF-7 cells mostly rendered higher drug sensitivity. In contrast ACHN appeared more sensitive to hypoxia,
giving slower proliferating cells, and consequently, was more resistant to most drugs.
Conclusions: A panel of standard cytotoxic agents was tested against five different human cancer cell lines
cultivated at normoxic, hypoxic and anoxic conditions. Results show that impaired chemosensitivity is not universal,
in contrast different cell lines behave different and some drugs appear even less effective in normoxia
than hypoxia.
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Tumor hypoxia
Solid tumors contain regions with mild (hypoxia) to severe
oxygen deficiency (anoxia), due to the lack of blood supply
to the growing tumor nodules [1-3]. Oxygen and nutrients
are essential for solid tumor growth, and when sufficient
oxygen is not provided growth arrest or necrosis occurs in
the unvascularized tumor core [4,5]. Neovascularization,
or angiogenesis, is required to keep the growing tumor ox-
ygenated and increased vascular density is correlated with
increased metastasis and decreased patient survival in
many cancers (reviewed by [6,7]).* Correspondence: joachim.gullbo@medsci.uu.se
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reproduction in any medium, provided the orDecreased oxygenation leads to various biochemical
responses in the tumor cells that ultimately can result in
either adaptation or cell death. Hypoxia-inducible factor
α (HIF-1α) is one of the most important transcription
factors and a regulator of gene products during hypoxia
[8]. Initial or moderate increase of HIF-1α levels could
lead to cell adaptation, and in the absence of oxygen
cancer cells adjust to their new microenvironment
mainly by angiogenesis stimulation by vascular endothe-
lial growth factor (VEGF) [9], inhibition of apoptosis via
Bcl-2 [10], modifying the cellular glucose/energy metab-
olism [11], adapting to acidic extracellular pH [12] and
up-regulation of proteins involved in metastasis [13].
The delicate balance between activators and inhibitorstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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nodules.
Hypoxia mediated resistance to radiotherapy and
chemotherapy
Hypoxic cells may be resistant to both radiotherapy and
conventional chemotherapy. Studies show that hypoxia
has a negative impact of radiotherapy on tumor cells in
various cancers such as mammary carcinoma [14], head
and neck carcinoma [15] and uterine cervix carcinoma
[16]. There are several non-excluding theories to explain
the fact that also conventional chemotherapy has less
effect on hypoxic tumor cells. The anarchic vascular pat-
tern characteristic of many tumors includes caliber
changes, loops and trifurcations [17]. This, and the dis-
tance between cell and blood vessel diminish the expos-
ure of the anticancer drug and also the proliferation of
the cells [4,18]. Since the cytotoxic effect is greater in
rapidly dividing cells, the slow proliferating tumor cells
far away from the blood vessels is less sensitive to
chemotherapy [1,18]. Hypoxia also selects for cells with
low expression of p53 and consequently p53-induced
apoptosis is reduced in hypoxic cells [19]. In normoxic
surroundings DNA injuries caused by some anticancer
drugs is more permanent, while in hypoxic surroundings
higher levels of restoration occurs [20]. Another associ-
ation between hypoxia and chemotherapy resistance is the
up-regulation of the multidrug resistance (MDR) genes
and over expression of the gene product P-glycoprotein
(P-gp), which is known to be involved in multidrug resist-
ance [21,22].
Different methods have been applied to study the
effect of a cytotoxic drug in an environment resembling
that of a tumor, i.e. with tumor cells in a hypoxic envi-
ronment. However, earlier in vitro studies on drug
effects in hypoxic cells have been performed with differ-
ent methods and have also yielded different results. For
example, hypoxic or anoxic cells may be generated by
incubation of monolayer cultures in hypoxic incubators
with constant O2, N2 and CO2 concentrations [23-26],
or by use of airtight containers, in which the oxygen
concentration in the gas phase is held at a constant level,
incubated in aerobic incubators [27]. The redox-
potential in the medium can also be altered with, for
example, cobalt chloride (CoCl2) to achieve chemical
hypoxia [28] or enzyme generated oxygen depletion by
adding glucose oxidase and catalase [29]. A three-
dimensional way of studying the effect of drugs in hyp-
oxia is the use of tumor spheroids [30,31]. Spheroids are
generated by culturing adherent cells and give a 3D cel-
lular context in which oxygen-, glucose- and ATP gradi-
ent varies [32]. After treatment, cell survival is measured
to determine the relative hypoxic toxicity of a drug. This
has previously been done by for example clonogenic [33]or non-clonogenic colorimetric assays using MTT
[23,34,35], sulforhodamine B [36] or by trypan blue
staining [24,26]. However, most of these investigations
have been done with limited series of drugs and/or cell
types, and slightly different conditions. In this work we
have screened a larger panel of drugs in five different
cell lines, to investigate their sensitivity to a panel of
chemotherapeutic agents under conditions of normoxia
(20% O2), hypoxia (1% O2), and anoxia (0.1% O2).
Methods
Cell lines
The in vitro analysis were carried out in a panel of can-
cer cell lines, including A2780 (ECACC Salisbury, UK),
ACHN, MCF-7, NCI-H69 (all American Type Culture
Collection, LGC Standards, Borås, Sweden) and U937-
GTB (kind gift from Kennet Nilsson, Department of
pathology, Uppsala University). The different cell lines
were selected as representatives of various kinds of
cancer types, including ovarian cancer (A2780), breast
cancer (MCF-7), renal adenocarcinoma (ACHN), small cell
lung cancer (H69) and a leukemic monocyte lymphoma
(U937). Cell growth medium RPMI 1640 (Sigma-Aldrich,
Stockholm, Sweden), supplemented with 10% heat-
inactivated fetal bovine serum (FCS; Sigma-Aldrich,
Stockholm, Sweden), 2 mmol/L L-glutamine, 100 μg/mL
streptomycin, and 100 U/mL penicillin (Sigma-Aldrich,
Stockholm, Sweden), was used to maintain A2780-,
ACHN-, H69- and U937 cell lines. MCF-7 was main-
tained in Minimum Essential Medium Eagle (M5650,
Sigma-Aldrich, Stockholm, Sweden), supplemented with
10% heat-inactivated FCS (Sigma-Aldrich, Stockholm,
Sweden), 2 mmol/L L-glutamine, 100 μg/mL streptomycin,
100 U/mL penicillin (Sigma-Aldrich, Stockholm, Sweden)
and 1 mM sodium pyruvate (P5280, Sigma-Aldrich,
Stockholm, Sweden). All cell lines were kept in 75 cm2
culture flasks (TPP, Trasadingen, Switzerland) at 37°C
in a humidified atmosphere of 95% air, 5% CO2. The
enzyme accutase (PAA, Pasching, Austria) was used to
detach the A2780-, ACHN- and HT29 cells from the
bottom of the flask and accumax (PAA, Pasching, Austria)
was used to separate the H69 cells and detach the MCF-7
cells from the flask.
Drugs and reagents
The drugs tested were selected as representatives of vari-
ous chemotherapeutic drug groups with different modes
of action. 5-fluorouracil (5-FU), cisplatin, docetaxel,
doxorubicin, etoposide, gemcitabine, irinotecan, melpha-
lan and vincristine were obtained from the Swedish
Pharmacy (Uppsala Sweden). Acriflavine, digitoxin,
digoxin, rapamycin, thalidomide and topotecan where
purchased from Sigma-Aldrich (Stockholm, Sweden),
mitomycin c from Medac (Varberg, Sweden), bortezomib
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and tirapazamine from Chemos GmbH (Regenstauf,
Germany). The drugs are listed in Table 1, including earlier
reports of effect(s) in hypoxia. The pharmaceutical prepa-
rations were dissolved according to instructions from
the manufacturer, the other drugs were dissolved in
dimetylsulfoxid (DMSO; Sigma-Aldrich, Stockholm,
Sweden) or dimethylacetamide (DMA; Sigma-Aldrich,
Stockholm, Sweden) and stored frozen in −70°C for max-
imum three months. Sterile phosphate buffered saline (PBS;
Sigma-Aldrich, Stockholm, Sweden) was used to dilute
the drugs to desirable concentrations. Fluoresceindiacetate
(FDA; Sigma-Aldrich, Stockholm, Sweden) was dissolved in
DMSO to a concentration of 10 mg/mL and kept frozen
(−20°C) as a stock solution protected from light.
Oxygen deprivation
The cells were seeded in duplicate in 96-well microtiter
plates (NUNC, Roskilde, Denmark). 180 μL cell suspension,Table 1 Drugs tested in this study, with previous reports of in
Drug Type of drug Effect in hypoxia
5-FU Antimetabolite pyrimidine
analog
Less effective in hypoxia in m
Acriflavine Antiseptic Inhibition of HIF dimerization
Bortezomib Proteasome inhibitor VEGF inhibitor in endothelia
multiple myeloma and liver
Cisplatin Platinum compound Less effective in hypoxia in t
Downregulate HIF in human
Digitoxin Cardiac glycoside HIF-1 inhibition in hepatobla
Digoxin Cardiac glycoside HIF-1 inhibition in prostate c
Docetaxel Mitosis inhibitor, taxane HIF-1 inhibition in ovarian an
Activity unchanged in prosta
Doxorubicin Antracycline,
topoisomerase II inhibitor
Inhibition of HIF activation in
Less effective in hypoxia in m
Etoposide Mitosis inhibitor,
epipodo-phyllotoxin
Less effective in hypoxia in t
cell lines
Gemcitabine Pyrimidine analog Less effective in hypoxia in t
Irinotecan Topoisomerase I inhibitor The metabolite SN38 inhibit
Melphalan Alkylating mustard analog Enhanced effect in hypoxia
Mitomycin c Quinone antibiotics Bioreductive in hypoxia in m
Less effective in hypoxia in t
Rapamycin Oral macrolide, mTOR-
inhibitor
Inhibits mTOR, downregulate
and colon cancer cell lines
Sorafenib Multikinase inhibitor VEGFR and PDGFR inhibitor
Thalidomide Anti-inflammatory Angiogenesis inhibitor in CA
Tirapazamine Bioreductive prodrug Reactive radical cause DNA-
Topotecan Topoisomerase I inhibitor Inhibit HIF-1α expression in
Vincristine Vinca alkaloid Inhibit HIF-1α expression in
Less effective in hypoxia in gwith the concentration of 100 000 cells/mL was added to
each well, blank wells containing medium only. The
normoxic set of plates was placed in an aerobic incubator
(atmospheric) and the hypoxic/anoxic set where moved to
a Ruskinn InVivo2 500 hypoxic incubator (Ruskinn Tech-
nology Ltd, Pencoed, UK) and where equilibrated at 37°C
in a humidified atmosphere of 5% CO2 and limited oxygen,
either 0.1% O2 or 1.0% O2. Hereafter 0.1% O2 is considered
as extreme deprivation of oxygen and will be referred to as
anoxia and 1.0% O2 will be referred to as hypoxia. After 18
hours pre-incubation, 20 μL of test solution were added to
each well (PBS to blank and control, drug solution to dupli-
cate test wells) and left to incubate for 72 hours. After the
incubation, measurement according to the fluorometric mi-
croculture cytotoxicity assay (FMCA) was performed.
The Fluorometric Microculture Cytotoxicity Assay FMCA
The non-clonogenic cell viability assay FMCA is based
on the fluorescence generated from the hydrolysis ofcreased or decreased effect in hypoxia
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Table 2 Mean IC50 values for all tested drugs in normoxia
A2780, ACHN, H69, MCF-7 and U-937
A2780 ACHN H69 MCF-7 U-937
5-FU 0.69 mM >1.0 mM >1.0 mM N/A 0.14 mM
Acriflavine 6.2 μM 12 μM 27 μM 61 μM 4.6 μM
Bortezomib 11 nM 0.63 μM 15 nM >3.0 μM 13 nM
Cisplatin ~9.3 μM 28 μM 0.11 mM 62 μM 2.8 μM
Digitoxin 0.11 μM 0.15 μM >20 μM N/A 70 nM
Digoxin 0.15 μM 0.81 μM N/A N/A 0.12 μM
Docetaxel 10 μM 4.0 μM 9.5 μM 25 μM <16 nM
Doxorubicin ~1.8 μM 4.7 μM 23 μM 29 μM 0.15 μM
Etoposide 34 μM 11 μM 17 μM >50 μM 0.17 μM
Gemcitabine ~4.8 mM >5.0 mM >5.0 mM >5.0 mM <1.6 μM
Irinotecan 38 μM 17 μM ~0.21 mM 93 μM 4.7 μM
Melphalan 18 μM 37 μM 0.13 mM 0.12 mM 6.0 μM
Mitomycin C ~53 μM 23 μM 37 μM 35 μM 0.70 μM
Rapamycin ~47 μM 28 μM 62 μM N/A 5.1 μM
Sorafenib 7.2 μM 15 μM ~13 μM 43 μM 7.3 μM
Thalidomide N/A >0.1 mM >0.1 mM >0.1 mM 0.17 mM
Tirapazamine 0.15 mM 64 μM 0.15 mM 0.14 mM 24 μM
Topotecan 15 μM 10 μM 9.5 μM <30 μM 0.12 μM
Vincristine 3.5 mM <0.1 mM N/A N/A <34 nM
N/A (not applicable) refers to an ambiguous IC50.
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intact cell membranes. The methodology is described by
Larsson et al. (1992) and also in detail in the protocol
article by Lindhagen et al. (2008) [67,68]. In short, cells
(20000/well) were pre-incubated at normoxia, hypoxia
or anoxia, where after drugs were added and the plates
incubated for 72 hrs, washed ones with PBS in a microti-
ter plate washer (Multiwash, Dynatech Laboratories) and
thereafter FDA (100 μl of 0.01 mg/mL FDA, Sigma-
Aldrich, Stockholm, Sweden) in a buffer, was added.
After 40 minutes incubation (37°C) the generated fluor-
escence was measured at 485/520 nm in a Fluoroskan II
(Labsystems, Helsinki Oy, Finland) and the survival
index (SI%) for each drug concentration was calculated.
All experiments were performed three times. From the
mean SI%-curves the half maximal inhibitory concentra-
tion (IC50) was determined using non-linear regression
analysis in Prism 5 Software Package (Graph Pad, San
Diego, CA). Cytotoxicity ratios (Ranox = anoxic IC50/
normoxic IC50 and Rhypox = hypoxic IC50/normoxic
IC50) were determined for each drug and cell line.
Statistical analysis
For the three obtained SI% replicates, Grubbs test was
used to detect and exclude significant outliers, with the
significance level of alpha = 0.05. Calculations of IC50
were made by the non-linear regression analysis in the
Prism 5 software. If the IC50 was ambiguous it was
reported as not applicable (N/A). If the suggested IC50
exceeded the highest tested concentration it was
reported only if the R2 exceeded 0.75 or SI% for the
highest concentration was under 75%, otherwise only de-
fined as > highest tested concentration. An approximate
(~) value was used as a true value when used to calculate
cytotoxicity ratios. An unpaired two-tailed t-test was
used to determine the significance levels of the ratios
(p < 0.05, p < 0.01 and p < 0.001).
Verifying hypoxia
To verify hypoxia and anoxia in the cells, microarray
analysis was performed as previously described [69] at
the Uppsala Array Platform (Department of Medical
Science, Science for Life Laboratory, Uppsala University,
Sweden). MCF-7 breast cancer cells was incubated either
in normoxic, hypoxic or anoxic surroundings, after 90
hours the cells were washed with PBS and total RNA
was prepared using RNeasy® Mini Kit (Qiagen AB,
Sollentuna, Sweden) according to the manufacturers
instructions. RNA concentration was measured with
ND-1000 spectrophotometer (NanoDrop Technologies,
Wilmington, DE) and RNA quality was evaluated
using the Agilent 2100 Bioanalyzer system (Agilent
Technologies Inc, Palo Alto, CA). 250 ng of total RNA
from each sample were used to generate amplifiedand biotinylated sense-strand cDNA from the entire
expressed genome according to the Ambion WT Expres-
sion Kit (P/N 4425209 Rev C 09/2009) and Affymetrix
GeneChip® WT Terminal Labeling and Hybridization
User Manual (P/N 702808 Rev. 6, Affymetrix Inc., Santa
Clara, CA). GeneChip® ST Arrays (GeneChip® Human
Gene 2.0 ST Array) were hybridized for 16 hours in a 45°C
incubator, rotated at 60 rpm. According to the GeneChip®
Expression Wash, Stain and Scan Manual (PN 702731 Rev
3, Affymetrix Inc., Santa Clara, CA) the arrays were then
washed and stained using the Fluidics Station 450 and fi-
nally scanned using the GeneChip® Scanner 3000 7G. The
raw data was normalized in the free software Expression
Console provided by Affymetrix (affymetrix.com) using
the robust multi-array average (RMA) method. Further in-
terpretation of the gene expression data was done by gene
set enrichment analysis (GSEA) [70] and the gene ontol-
ogy (GO) bioinformatic tool: database for annotation,
visualization and integrated discovery (DAVID) [71].
Results
The normoxic IC50-values for all drugs in the panel in
the cell lines (A2780, ACHN, H69, MCF-7 and U-937)
are shown in Table 2 and the IC50-ratios of hypoxic or
anoxic vs normoxic cells are displayed in Table 3. If the
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it was considered as equally effective in anoxic/hypoxic
and normoxic cells. If the ratio exceeded 1.2 the effect of
the drug was less effective in anoxia/hypoxia, and if the
ratio was less than 0.8 the drug was more effective in
anoxia/hypoxia.
Trends in the different cell lines
The ovarian carcinoma cell line A2780 was less sensi-
tive to most drugs (ratio >1.2 in nine of 17 drugs
evaluable for IC50) in anoxia (0.1% O2), but surpris-
ingly was more or equally sensitive (ratio <1.2 in 14
of 16 drugs) to the administered drugs in hypoxia
(1.0% O2) compared to normoxia. The renal adeno-
carcinoma ACHN was less sensitive to the effects of
most drugs in both anoxic (ratio >1.2 in 10 of 12
drugs) and hypoxic cells (ratio >1.2 in 11 of 15 drugs)
compared to normoxic cells. Compared to normoxic
cells, oxygen deprived H69 (small lung cancer) and
MCF-7 (breast cancer) cells were generally more sen-
sitive to most drugs (for hypoxia the ratio was <0.8
in 11 of 13, and in 6 of 7 drugs respectively). U-937
(lymphoma) cells were slightly more, or equally, sensi-
tive to most drugs in a hypoxic environment.Table 3 Ratios Ranox and Rhypox for all tested drugs in all cell
A2780 ACHN H6
Anoxia Hypoxia Anoxia Hypoxia An
5-FU 0.29*** N/A N/A N/A N/A
Acriflavine 0.56 N/A 2.4* 1.0 0.19
Bortezomib 0.10*** 0.20*** >4.0** >6.0** 0.14
Cisplatin 1.6 0.90 3.6** 1.1 0.22
Digitoxin 3.6 0.94 N/A >133** <0.
Digoxin 2.4 1.1 N/A >80** N/A
Docetaxel 2.3 1.0 44*** 7.3** 1.0
Doxorubicin 1.3 0.50 3.5** 1.1 1.1
Etoposide 1.3 0.73 >3.7** >6.5** 0.46
Gemcitabine N/A 0.62 N/A N/A N/A
Irinotecan 1.3 1.3 5.3*** >2.7** 0.32
Melphalan 2.0 2.6 4.9*** 5.1** 0.24
Mitomycin C 0.17*** 0.22 1.1 2.0** 0.11
Rapamycin 1.2 0.34 1.2 1.3 0.14
Sorafenib 0.85 0.87 1.6* 1.2 0.58
Thalidomide N/A N/A N/A N/A <0.
Tirapazamine 0.044*** 0.045*** 0.1*** 0.10*** 0.02
Topotecan 0.023*** 0.50 N/A 1.5 N/A
Vincristine 5.0** 0.010 N/A N/A N/A
Ranox = anoxic IC50/normoxic IC50 and Rhypox = hypoxic IC50/normoxic IC50. Ratio val
<0.8 = more effective in anoxia/hypoxia, >1.2 = more effective in normoxia, N/A =
two-tailed t-test.Trends between the different drugs
In general cisplatin, mitomycin c and tirapazamine
(Figure 1) were more effective in anoxic or hypoxic
environment (e.g. tirapazamine was significantly more
active in all evaluated cell lines; cisplatin in H69,
MCF-7 and U-937; and mitomycin C in A2780, H69,
MCF-7 and U-937). Acriflavine, bortezomib, doxorubi-
cin and etoposide also showed a slightly higher effect in
anoxia and hypoxia compared to normoxia. Sorafenib and
irinotecan (Figure 2) was apparently less effective in most
anoxic and hypoxic cells (e.g. sorafenib was significantly
less active in ACHN, MCF-7 and U-937), while docetaxel
and melphalan had a slight decrease in effect in most
anoxic and hypoxic cells. The other tested drug did not
present with a clear tendency for being more or less sensi-
tive in hypoxia or anoxia, the different cell types behaved
differently (Table 3).
Sensitivity of untreated cells
The control/blank signal relationship between oxygen
deprived and oxygenated cells were calculated to evalu-
ate the proliferating abilities of the cells, since a dimin-
ished proliferative capacity is likely to render lower
sensitivity to most cytotoxic drugs. The mean ratio oflines
9 MCF-7 U-937
oxia Hypoxia Anoxia Hypoxia Anoxia Hypoxia
N/A N/A N/A 1.7** 1.5
** 0.23** N/A 0.52 0.99 0.81*
** 0.76 N/A N/A 1.1 0.85
** 0.21** 0.37*** 0.49** 0.52*** 0.43***
050 <0.56 N/A N/A 2.0 0.95
<0.24 N/A N/A 1.2 0.85
1.8 0.75 0.58 N/A N/A
<0.46 >2.1* 0.59* 0.69* 0.61**
* 0.75 N/A N/A 0.87 0.80*
N/A N/A N/A N/A N/A
N/A >2.7 N/A 1.1 0.86
** N/A 0.89 N/A 0.61** 0.55**
*** 0.18** 0.63* 0.31*** 0.45*** 0.44***
** 0.08** N/A N/A 0.34* 1.8
1.8 1.5 1.4 2.0 1.2
89* N/A <0.28 N/A 0.21*** <0.44*
5*** 0.042*** 0.055*** 0.062*** 0.072*** 0.094***
0.31** N/A N/A 2.2* 0.72
N/A N/A N/A N/A >1
ue for a drug: 0.8-1.2 = equally effective in anoxia/hypoxia and normoxia,
not applicable. Significance levels * p < 0.05; ** p < 0.01; *** p < 0.001;
Cisplatin ACHN 





















































































































Figure 1 The effect of drugs generally more effective in oxygen deprived environment. Cisplatin (A and B), mitomycin c (C and D) and
tirapazamine (E and F) in ACHN (renal adenocarcinoma) and H69 (small lung cancer) cell lines in anoxic, hypoxic and normoxic surroundings.
Error bars denote SEM.
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normoxic cells are presented in Table 4. A value below 1
(a lower signal) indicates a lower cell number in control
wells after 18 + 72 hrs incubation in oxygen deprived
cells vs. normoxic cells, as would be expected theoretic-
ally. However, the comparably high cell density
(100,000/mL, selected to give the best signal-noise ratio)
and the 90 hrs total incubation will probably also lead to
some extent of growth inhibition due to confluence and
cell-cell inhibition in the normoxic cells during the
experiment. In such cases it is possible that growth
inhibition (i.e. cytostatic effects, in contrast to cell killing
cytotoxic effects) in the end of the experiments may be
underestimated. Low ratios were observed in ACHN,
U-937 and anoxic A2780 cells, which appear to correlatewith the lower sensitivity to most drugs in hypoxic/anoxic
ACHN and anoxic A2780 cells. However, it appears that
U-937 is the most sensitive cell line to oxygen deprivation
in the panel, and this is not reflected by the changes in
chemosensitivity. Surprisingly, a high ratio was observed
in H69, and indeed this cell line was also generally more
sensitive to most of the drugs tested. No significant dis-
crepancy was observed in MCF-7, who still was slightly
more sensitive to the drugs in hypoxia.
Hypoxia verification
Gene set enrichment analysis shows a distinct pattern of
hypoxia-associated gene sets among the genes up-
regulated when incubated in hypoxia [72]. Gene expres-
sion data confirmed that cells grown in oxygen-deprived
Docetaxel ACHN













































































Figure 2 The effect of drugs generally less effective in oxygen deprived environment. Docetaxel (A and B) and irinotecan (C and D) in
ACHN (renal adenocarcinoma) and H69 (small lung cancer) cell lines in anoxic, hypoxic and normoxic surroundings. Error bars denote SEM.
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ated with hypoxia such as HIF1α (Figure 3). A clear pat-
tern was also seen in the over-represented GO terms
with the top result being the “response to hypoxia”
(adjusted p-value 5.19E-13) group of 16 genes, also for
the up-regulated genes. Raw and normalized expression
data have been deposited at Gene Expression Omnibus
with accession number GSE47009.Discussion
The concentration of oxygen in human tumors widely
varies, and it is not uncommon to find areas with oxy-
gen pressure lower than 2.5 mmHg, and the extent of
hypoxia seems to be tumor stage and size independentTable 4 Mean ratio of the control/blank signal in cells








Ratio value ~1 = equal cell number at 90 h in anoxia/hypoxia or normoxia, <0.8 =
lower cell number in anoxia or hypoxia, >1.2 = higher cell number in anoxia/
hypoxia. Significance levels * p < 0.05; ** p < 0.01; paired, two-tailed t-test.[73]. Radiotherapy and conventional chemotherapies are
often less effective in oxygen depressed cells [74]. There-
fore it is of great importance to make use of the oxygen
deprivation and find drugs that are more effective in
hypoxic tumor cells.
In our study the untreated hypoxic and anoxic ACHN
and U-937 cells, as well as anoxic A2780 cells were
less proliferative than corresponding normoxic cells
(i.e. most sensitive to oxygen deprivation). Indeed re-
sults also showed that ACHN and anoxic A2780 were
more resistant to most drugs under reduced oxygen
pressure, which is expected in view of the fact that
slow proliferating tumor cells are less sensitive to
chemotherapy. Interestingly the reversed effect could
be observed in H69, where oxygen deprived cells
(most surprisingly) appeared more viable and was a
lot more sensitive to drugs. MCF-7 cells were also
more sensitive to drugs in an oxygen-deprived envir-
onment but, in difference to H69, the MCF-7 cells
displayed no proliferative difference in normoxic and
hypoxic or anoxic surroundings. Hypoxia mostly occurs in
tumors and therefore different cell lines with a solid tumor
origin were the most interesting objects in this study. The
leukemic lymphoma cell line U-937 is not a solid tumor
per se, but was included in the study for comparison. Un-
treated U-937 cells were less viable in an oxygen-deprived
environment, but did not display any real difference in sen-
sitivity to chemotherapy in hypoxia or anoxia.
Figure 3 Gene set enrichment analysis. Results based on gene expression data from breast cancer cells (MCF-7 cell line) incubated in hypoxia
(1.0% O2) compared to normoxia (20% O2) for 90 hrs. Enrichment profile shows an association of hypoxia-associated genes among the genes
up-regulated when incubated in hypoxia.
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environment; cisplatin, mitomycin c and tirapazamine.
Earlier studies have revealed contradictive results, showing
hypoxic cells to be more resistant to cisplatin in some cell
lines [35] but also showing cisplatin to be a HIF-1 inhibitor
[42]. Mitomycin c was also clearly more effective in most
of the oxygen deprived cell lines. Hypoxia induces the
enzymatic system capable of activating mitomycin c [75]
and is therefore considered more toxic to hypoxic cells
[46,54]. However, mitomycin c has also been shown to be
less effective in hypoxic testicular germ cell tumor cell lines
[35] and was in our study less effective in ACHN under
hypoxic and anoxic conditions. Tirapazamine was signifi-
cantly more effective in all oxygen deprived cell lines, and
our results for tirapazamine highly correspond to previous
studies of this bioreductive prodrug [62]. Tirapazamine is
activated under hypoxic conditions by a reductase enzyme,
in which creating a highly reactive molecule that in turn
causes single- and double strand breaks in the DNA of
tumor [61].
The drugs with increased resistance in hypoxic and
anoxic cells were docetaxel, irinotecan, melphalan and
sorafenib. Docetaxel has been shown to both influence
[44] and not influence [42] the HIF-1α protein accumu-
lation. Although this study proposed that docetaxel wasassociated with increased drug resistance in most cells
in anoxia and hypoxia, other studies has implied that
some cell lines was not [45]. In accordance to this study,
irinotecan has earlier been shown to be less effective
under hypoxic conditions [35]. Irinotecan decreases the
expression of HIF-1α and VEGF under both normoxic
and hypoxic conditions [51], which could be why there
is no difference in effect in some cell lines; here U-937.
Melphalan is an alkylating agent with an enhanced effect
in hypoxia [52] and in HIF-1α inhibited cells [53]. Al-
though the correlation between hypoxia and melphalan
resistance was not distinct, both A2780 and ACHN were
clearly less sensitive and U-937 more sensitive, in oxygen
deprived cells. Sorafenib inhibits vascular endothelial
growth factor receptor (VEGFR) and platelet-derived
growth factor receptor (PDGFR) signaling [58], thus one
might hypothesize that sorafenib would be more potent
under hypoxic conditions. With respect to the cell lines
used in this report, we have found no information on
SCLC cell line NCI-H69 expression or dependence on
VEGF signaling. The renal cell adenocarcinoma ACHN
has a low normal baseline secretion of VEGF to cell
growth medium [76], a secretion that may be inhibited
by sorafenib, and to which ACHN is sensitive [77]. The
breast cancer cell line MCF-7 has been described with a
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autocrine (intracrine) survival factor through its binding
to VEGFR-1 [78], and cell line is sensitive to treatment
with sorafenib, which also appear to down-regulate
hypoxia induced HIF-1α expression [79]. The ovarian
carcinoma cell line A2780 expresses VEGFR-1 [80],
but its sensitivity to sorafenib has not been described
previously. In this study sorafenib was less effective in
hypoxic and anoxic ACHN, MCF-7 and U-937 cells,
which may be related to the mono-culture assay with
no communicating stroma cells.
In the study presented herein we have emphasized to
isolate hypoxia as the variable in the experiments, all
other factors (nutrients in medium, cell density, incuba-
tion time etc.) were standardized, and all arms of each
replicate (normoxic vs anoxic/hypoxic) were analyzed
simultaneously. There are several environmental factors
in solid tumors that may be studied, e.g. the low nutrient
supply (analogous with oxygen supply), interaction with
stroma cells, acidity (in part secondary to hypoxia, and
metabolism), as well as proliferation of the tumor cells.
These factors may be studied individually (as in this
report), or by assays including several aspects, for
example by the use of spheroid cultures or prolonged
incubation times beyond confluency. Furthermore, since
different drugs act on cancer cells in different ways
resulting in cytostatic (growth inhibitory) or cytotoxic
(cell killing) effects, different readouts would probably
yield different results. The FMCA-based IC50-value used
in this report is based on survival indices (compared to
untreated control) at the end of the experiment, and is
thus the result of both antiproliferative and toxic effects.
Conclusion
Our results show that impaired chemosensitivity is not
universal, in contrast different cell lines behave different
and some drugs appear even less effective in normoxia.
Part of the results obtained with this method, as prob-
ably with any model of oxygen deficiency, can be directly
explained by decreased proliferation when cells are
deprived of oxygen. However, this is clearly not the only
variable, as some cells appeared to increase their prolif-
eration and sensitivity under low oxygen pressure. Fur-
thermore, hypoxia is not the only limiting factor of
proliferation in a small tumor, but other limiting factors,
such as the physical space, distribution of nutrients and
drugs, metabolism and removal of waste products (with
a succeeding change in pH), may also be utilized as
therapeutic targets. These and other factors could also
be evaluated in a similar screen study.Competing interests
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